Trade ARCA Biopharma - ABIO CFD
Active clients monthly
Monthly investing volume
Withdrawn each month
- Historical Data
- Long position overnight fee
- Short position overnight fee
- Overnight fee time
- 21:00 (UTC)
- Min traded quantity
- Stock exchange
- United States of America
- Commission on trade
- Last Week
- Last Month
- Last Year
- Last two Years
|Average Vol. (3m)||3.22418|
|52 wk Range||N/A|
|Dividend (Yield %)||N/A|
|Next Earnings Date||Aug 2, 2022|
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
ARCA Biopharma Company profile
About Arca Biopharma Inc
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.
BRIEF: For the fiscal year ended 31 December 2021, Arca Biopharma Inc revenues was not reported. Net loss increased 98% to $19.3M. Higher net loss reflects Other -Research and development increase from $5M to $13.7M (expense), other expenses1 increase of 8% to $5.1M (expense), Stock-based Compensation in SGA increase from $17K to $337K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.07 to -$1.39.
Common Stock $.001 Par, Insiders own 3.59% . IPO 8/97, 3M shares @$14 by LehmanBrothers, Inc. PO 3/04, 5M shares @ $13 by UBS SecuritiesLLC. 2/03, Company merged with Variagenics, Inc. andchanged name from Hyseq, Inc. 01/09, Name changed fromNuvelo, Inc. 03/13, 1-for-6 reverse stock split. 9/15, 1-for-7 reverse stock split.
|Industry:||Bio Therapeutic Drugs|
8001 Arista Place
Australia interest rate: Can AUD find relief from hawkish central bank?
Investors have upgraded their expectations for the central bank for Tuesday’s decision14:09, 4 July 2022
Why is the silver price falling? Sinks below the pivotal $20 mark
Silver, which has been hovering around a 2-year low for a while now, has just dipped below $2013:00, 4 July 2022
Gold recovers slightly, silver falls to more than 2-year lows
Gold recovered slightly from a recent 5-month low, as silver fell to more than 2-year lows on Monday morning13:00, 4 July 2022
How will GSK shareholders get their Haleon stock? GlaxoSmithKline spin-off to start trading
GSK share price: How will shareholders get their Haleon stock after the demerger?12:48, 4 July 2022
Currys (CURY) results: Can the electrical retailer curry favour with investors?
Is the loss of consumer confidence set to be the only headwind that Currys faces?11:27, 4 July 2022
People Also Watch
US Tech 100
|Long position overnight fee||-0.0092%|
|Short position overnight fee||0.0008%|
|Overnight fee time||21:00 (UTC)|
Still looking for a broker you can trust?
Join the 400.000+ traders worldwide that chose to trade with Capital.com